← Compound index
COMPOUND RECORD / LIBIDON

LibidonЛибидон

An oral peptide mixture made from calf prostate tissue, described in a Russian institute clinical report.

Source linked

What the studies found

Comparison in people · 2011

Libidon: clinical report reproduced in the Russian institute-report collection (2011)

Chronic prostatitis · mean urinary flow
23.5 vs 19.8 mL/sAdjunctive Libidon versus usual care after 30 days. Shared baseline column 17.3 mL/s.Adjunct arm marked p < 0.05 versus baseline.
Benign prostatic hyperplasia · mean urinary flow
17.5 vs 14.2 mL/sShared baseline column 11.3 mL/s.Adjunct arm marked p < 0.05 versus baseline.
Peak urinary flow
26.5 vs 24.4 mL/s in prostatitis and 20.5 vs 18.2 mL/s in hyperplasiaAdjunctive Libidon versus usual care.The report marks neither row as significant relative to baseline.

In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.

More reported outcomes
Reported adverse effects
None describedSystematic monitoring and harms by arm are unavailable.
Study notes · methods, sources and limitations

Participants or model 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending

Design 48 men received adjunctive Libidon (28 chronic prostatitis, 20 benign prostatic hyperplasia). Another 22 received usual care. Used uroflowmetry, symptoms and ultrasound.

Important limitations

  • The signed original and protocol have not been authenticated. Allocation and blinding are not established; diagnostic subgroups, 22 separately described controls and symptom-specific denominators require reconciliation. Concurrent treatment prevents attribution to Libidon alone. No equivalence to Prostatilen or Prostamax is established.
  • The tables give a single baseline per diagnostic group and do not state comparator subgroup counts. The significance markers do not test superiority over usual care.

Commercial brochure, PDF pages 47–50; institute original unauthenticated · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Libidon

Identity / background source ↗

Research background

A prostate-derived peptide mixture described in a Russian institute-report reproduction. It is a distinct preparation from Prostatilen and the synthetic peptide Prostamax.

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Commercial reproduction of an adjunct-treatment comparison; original unauthenticated

Study methods

Original preparation and study methods await verification

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

Russian reproduction and uroflowmetry tables checked. A separate report scan is linked.

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The report describes 48 treated men and 22 controls. The urinary-flow tables use a shared baseline per diagnosis. Comparator subgroup sizes and allocation remain unclear.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2011

Libidon: clinical report reproduced in the Russian institute-report collection (2011)

In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.

Study notes and original source
2011Human comparative studyRussian-language source

Libidon: clinical report reproduced in the Russian institute-report collection (2011)

Prostate-derived peptide mixture · Institute report — commercial reproduction

Format: Russian PDF brochure · Reviewed: Methods and urinary flow tables checked in the Russian reproduction

Medical Center, St Petersburg Institute of Bioregulation and Gerontology (attributed in reproduction) · Commercial brochure, PDF pages 47–50; institute original unauthenticated

In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.

Results and tables

Reported findings and study design

48 men received adjunctive Libidon (28 chronic prostatitis, 20 benign prostatic hyperplasia). Another 22 received usual care. Used uroflowmetry, symptoms and ultrasound.

Population or model 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending

Dose, route and schedule

One 10 mg oral capsule twice daily with meals for 30 days alongside usual treatment. The comparator received usual treatment alone.

Protocol source ↗ · Russian institute-report reproduction, methods and Tables 1–3

Results · Russian institute-report reproduction, methods and Tables 1–3
MeasureResultComparison, timing and statistics
Chronic prostatitis · mean urinary flow23.5 vs 19.8 mL/sAdjunctive Libidon versus usual care after 30 days. Shared baseline column 17.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline.
Benign prostatic hyperplasia · mean urinary flow17.5 vs 14.2 mL/sShared baseline column 11.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline.
Peak urinary flow26.5 vs 24.4 mL/s in prostatitis and 20.5 vs 18.2 mL/s in hyperplasiaAdjunctive Libidon versus usual care. · The report marks neither row as significant relative to baseline.
Reported adverse effectsNone describedSystematic monitoring and harms by arm are unavailable.
Tables 2–3 · uroflowmetry
Tables 2–3 · uroflowmetry
MeasureBaseline columnUsual careUsual care + Libidon
Prostatitis · mean flow (mL/s)17.3 ± 1.219.8 ± 1.623.5 ± 2.4*
Prostatitis · peak flow (mL/s)22.1 ± 2.324.4 ± 2.126.5 ± 3.1
Hyperplasia · mean flow (mL/s)11.3 ± 1.214.2 ± 1.417.5 ± 1.6*
Hyperplasia · peak flow (mL/s)16.1 ± 2.318.2 ± 1.920.5 ± 2.1

Asterisks indicate p < 0.05 versus baseline. The report does not identify the type of ± term.

The tables give a single baseline per diagnostic group and do not state comparator subgroup counts. The significance markers do not test superiority over usual care.

Source for these results ↗ · Reviewed 2026-11-13

Population / setting
48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
Source reviewed
Russian institute-report reproduction, methods and Tables 1–3
Study limitations
  • The signed original and protocol have not been authenticated.
  • Allocation and blinding are not established; diagnostic subgroups, 22 separately described controls and symptom-specific denominators require reconciliation.
  • Concurrent treatment prevents attribution to Libidon alone. No equivalence to Prostatilen or Prostamax is established.

Reviewed 2026-11-13.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗